Tranexamic acid does not reduce risk of death in GI bleed


Background: TXA is an anti-fibrinolytic agent that decreases surgical bleeding and reduces death resulting from bleeding in trauma and postpartum hemorrhage. A 2012 Cochrane review suggested a reduction in mortality with use of TXA in patients with GI bleed, but previous trials were small with a high risk of bias.

Andrew Chung, MD, division of hospital medicine, Mount Sinai Health System, New York

Dr. Andrew Chung

Study design: Randomized, double-blind, placebo-controlled trial.

Setting: 164 hospitals in 15 countries.

Synopsis: A total of 12,009 patients presenting with suspected significant upper or lower GI bleeding were randomized to receive either high-dose TXA or placebo. Death resulting from bleeding within 5 days (primary outcome) was similar in the two groups (3.7% with TXA and 3.8% with placebo; relative risk, 0.99; 95% confidence interval, 0.82-1.18). All-cause mortality at 28 days was also similar (9.5% with TXA and 9.2% with placebo; RR, 1.03; 95% CI, 0.92-1.16).

There was an increase in venous thromboembolism (VTE; deep vein thrombosis or pulmonary embolism) in the TXA group versus the placebo group (0.8% with TXA and 0.4% with placebo; RR, 1.85; 95% CI, 1.15-2.98), as well as an increase in seizure events (0.6% with TXA and 0.4% with placebo; RR, 1.73; 95% CI, 1.03–2.93).

Bottom line: TXA did not reduce mortality risk in patients with upper or lower GI bleeding and should not be used in the routine management of GI bleed.

Citation: Roberts I et al. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet. 2020;395(10241):1927-1936. doi: 10.1016/S0140-6736(20)30848-5.

Dr. Chung is a hospitalist in the Division of Hospital Medicine, Mount Sinai Health System, New York.

Recommended Reading

Acid suppression therapy increases intestinal colonization of MDROs
The Hospitalist
Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis may not be effective
The Hospitalist
C. Diff eradication not necessary for clinical cure of recurrent infections with fecal transplant
The Hospitalist
COVID-19: New GI symptoms don’t raise death risk in IBD
The Hospitalist
Should hospitalists use albumin to treat non-SBP infections in patients with cirrhosis?
The Hospitalist
Rivaroxaban’s single daily dose may lead to higher bleeding risk than other DOACs
The Hospitalist
A pill for C. difficile works by increasing microbiome diversity
The Hospitalist
Timing of endoscopy for acute upper GI bleeding
The Hospitalist
Is ERCP indicated in gallstone pancreatitis without cholangitis?
The Hospitalist
Oakland score identifies patients with lower GI bleed at low risk for adverse events
The Hospitalist
   Comments ()